Ethnic and genetic determinants of cardiovascular response to the selective α2-adrenoceptor agonist dexmedetomidine

Hypertension

Volumn 51, Issue 2, 2008, Pages 406-411

  Kurnik, Daniel ^a   Muszkat, Mordechai ^a   Sofowora, Gbenga G ^a   Friedman, Eitan A ^a   Dupont, William D ^a   Scheinin, Mika ^b   Wood, Alastair J J ^a   Stein, C Michael ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Cardiovascular physiology; Dexmedetomidine; Ethnic groups; G protein beta3 subunit; Pharmacogenetics; Receptors, adrenergic, 2

Indexed keywords

ALPHA 2C ADRENERGIC RECEPTOR; CATECHOLAMINE; DEXMEDETOMIDINE; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT 3; NORADRENALIN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RESPONSE; CATECHOLAMINE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG RESPONSE; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEART RATE; HEREDITY; HUMAN; INDIVIDUALITY; MALE; NORADRENALIN BLOOD LEVEL; NORMAL HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC ALPHA-AGONISTS; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CYTOSINE; DEXMEDETOMIDINE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; MALE; NOREPINEPHRINE; OSMOLAR CONCENTRATION; RECEPTORS, ADRENERGIC, ALPHA-2; SEQUENCE DELETION; SINGLE-BLIND METHOD; THYMINE; VARIATION (GENETICS);

EID: 38549107556     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.098939     Document Type: Article

References (28)

1. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328:914-921.
2. Materson BJ, Reda DJ. Correction: single-drug therapy for hypertension in men. N Engl J Med. 1994;330:1689.
3. Lang CC, Stein CM, He HB, Belas FJ, Blair IA, Wood M, Wood AJ. Blunted blood pressure response to central sympathoinhibition in normotensive blacks: increased importance of nonsympathetic factors in blood pressure maintenance in blacks. Hypertension. 1997;30:157-162.
4. Nürnberger J, Dammer S, Mitchell A, Siffert W, Wenzel RR, Gossl M, Philipp T, Michel MC, Schäfers RF. Effect of the C825T polymorphism of the G protein beta 3 subunit on the systolic blood pressure-lowering effect of clonidine in young, healthy male subjects. Clin Pharmacol Ther. 2003;74:53-60.
5. Neumeister A, Charney DS, Belfer I, Geraci M, Holmes C, Sharabi Y, Alim T, Bonne O, Luckenbaugh DA, Manji H, Goldman D, Goldstein DS. Sympathoneural and adrenomedullary functional effects of alpha2C-adrenoreceptor gene polymorphism in healthy humans. Pharmacogenet Genomics. 2005;15:143-149.
6. Masuki S, Dinenno FA, Joyner MJ, Eisenach JH. Selective alpha2-adrenergic properties of dexmedetomidine over clonidine in the human forearm. J Appl Physiol. 2005;99:587-592.
7. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45:142-161.
8. Angst MS, Ramaswamy B, Davies MF, Maze M. Comparative analgesic and mental effects of increasing plasma concentrations of dexmedetomidine and alfentanil in humans. Anesthesiology. 2004;101:744-752.
9. Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000;93:382-394.
10. Kurnik D, Muszkat M, Friedman EA, Sofowora GG, Diedrich A, Xie HG, Harris PA, Choi L, Wood AJ, Stein CM. Effect of the alpha2C-adrenoreceptor deletion322-325 variant on sympathetic activity and cardiovascular measures in healthy subjects. J Hypertens. 2007;25:763-771.
11. Livak KJ. SNP genotyping by the 5′-nuclease reaction. Methods Mol Biol. 2003;212:129-147.
12. He HB, Deegan RJ, Wood M, Wood AJ. Optimization of high-performance liquid chromatographic assay for catecholamines. Determination of optimal mobile phase composition and elimination of species-dependent differences in extraction recovery of 3,4-dihydroxybenzylamine. J Chromatogr. 1992;574:213-218.
13. Ji QC, Zhou JY, Gonzales RJ, Gage EM, El Shourbagy TA. Simultaneous quantitation of dexmedetomidine and glucuronide metabolites (G-Dex-1 and G-Dex-2) in human plasma utilizing liquid chromatography with tandem mass spectrometric detection. Rapid Commun Mass Spectrom. 2004;18:1753-1760.
14. Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med. 2002;347:1135-1142.
15. Siffert W. G protein polymorphisms in hypertension, atherosclerosis, and diabetes. Annu Rev Med. 2005;56:17-28.:17-28.
16. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-151.
17. Stein CM, Lang CC, Xie HG, Wood AJ. Hypertension in black people: study of specific genotypes and phenotypes will provide a greater understanding of interindividual and interethnic variability in blood pressure regulation than studies based on race. Pharmacogenetics. 2001;11:95-110.
18. Stein CM, Lang CC, Singh I, He HB, Wood AJ. Increased vascular adrenergic vasoconstriction and decreased vasodilation in blacks. Additive mechanisms leading to enhanced vascular reactivity. Hypertension. 2000;36:945-951.
19. Virtanen R, Savola JM, Saano V, Nyman L. Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist. Eur J Pharmacol. 1988;20:150:9-14.
20. Muszkat M, Sofowora GG, Wood AJ, Stein CM. Alpha2-adrenergic receptor-induced vascular constriction in blacks and whites. Hypertension. 2004;43:31-35.
21. Small KM, Forbes SL, Rahman FF, Bridges KM, Liggett SB. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem. 2000;275:23059-23064.
22. 2C Adrenergic Receptors Predispose to Hypertension in Blacks? Hypertension. 2006;47:1140-1146.
23. Canham RM, Das SR, Leonard D, Abdullah SM, Mehta SK, Chung AK, Li JL, Victor RG, Auchus RJ, Drazner MH. Alpha2cDel322-325 and beta1Arg389 adrenergic polymorphisms are not associated with reduced left ventricular ejection fraction or increased left ventricular volume. J Am Coll Cardiol. 2007;49:274-276.
24. Brede M, Wiesmann F, Jahns R, Hadamek K, Arnolt C, Neubauer S, Lohse MJ, Hein L. Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. Circulation. 2002;106:2491-2496.
25. Bruck H, Schwerdtfeger T, Toliat M, Leineweber K, Heusch G, Philipp T, Nürnberg P, Brodde OE. Presynaptic alpha-2C adrenoceptor-mediated control of noradrenaline release in humans: Genotype- or age-dependent? Clin Pharmacol Ther. 2007; doi:10.1038/sj.clpt. 6100181.
26. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, Sharma AM, Ritz E, Wichmann HE, Jakobs KH, Horsthemke B. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet. 1998;18:45-48.
27. Schäfers RF, Nurnberger J, Rutz A, Siffert W, Wenzel RR, Mitchell A, Philipp T, Michel MC. Haemodynamic characterization of young normotensive men carrying the 825T-allele of the G-protein beta3 subunit. Pharmacogenetics. 2001;11:461-470.
28. Lang CC, Stein CM, Nelson RA, He HB, Belas FJ, Blair IA, Wood M, Wood AJ. Sympathoinhibitory response to clonidine is blunted in patients with heart failure. Hypertension. 1997;30:392-397.